Vernalis PLC (LON:VER) had its stock rating reiterated as ‘Add’ in a report released by analysts at Numis Securities.
Numis Securities today set a target price of 29 on the company’s stock. According to the analyst this now indicates there is a potential increase of 32.09% from Vernalis PLC’s current price of 21.96.
Over the last twelve months Vernalis PLC’s stock price has decreased by -56.64% from 50.63 to 21.96.
There are currently 526,351,000 shares in issue with a current share value of 21.96 giving Vernalis PLC a market capitalisation of 115.56M GBp .
Vernalis PLC (LON:VER) has a 50 day moving average of 24.55 and a 200 day moving average of 31.87. The 52 week high for the share price is 51.95 while the 52 week low for the stock is 20.
Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders. The Company markets three products, including Tuzistra XR in the United States prescription cough cold market; Moxatag, which is a once daily amoxicillin approved in the United States for tonsillitis and pharyngitis, and frovatriptan, which is an acute treatment for migraine. The Company also has four over prescription cough cold products under development and a pipeline of new chemical entity (NCE) development programs and research collaborations.